Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARIO S CUERVO

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1578664363
CMS profile
749946
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,601.86

76 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,601.86 76

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–76 of 76 matching records. This page contains 26 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARIO S CUERVO

NPI 1578664363 · CMS profile ID 749946

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–76 of 76 matching records. This page contains 26 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1578664363?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARIO S CUERVO, NPI 1578664363, CMS profile ID 749946. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–76 of 76 matching records. This page contains 26 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578664363?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). MARIO S CUERVO, NPI 1578664363, CMS profile ID 749946. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–76 of 76 matching records. This page contains 26 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578664363?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
MARIO S CUERVO, NPI 1578664363, CMS profile ID 749946, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–76 of 76 matching records. This page contains 26 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1578664363?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

76 matching records · $1,601.86 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 76 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–76 of 76.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Pharmaceuticals, Inc $18.2204/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077967560 CMS
Otsuka America Pharmaceutical, Inc. $20.7304/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118880576 CMS
ABBVIE INC. $21.9704/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103520498 CMS
Teva Pharmaceuticals USA, Inc. $20.0004/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151720596 CMS
Almatica Pharma LLC $17.5104/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137560757 CMS
Alkermes, Inc. $111.6404/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120485380 CMS
ABBVIE INC. $13.9704/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103520496 CMS
Teva Pharmaceuticals USA, Inc. $23.6204/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151720594 CMS
ABBVIE INC. $18.5603/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103520494 CMS
Otsuka America Pharmaceutical, Inc. $17.1003/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118880574 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $20.7403/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143211904 CMS
Janssen Pharmaceuticals, Inc $34.6903/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077967744 CMS
Otsuka America Pharmaceutical, Inc. $28.2203/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118880572 CMS
Janssen Pharmaceuticals, Inc $20.0003/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077968008 CMS
Indivior Inc. $26.3602/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144526364 CMS
Teva Pharmaceuticals USA, Inc. $15.2402/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151720544 CMS
Otsuka America Pharmaceutical, Inc. $21.1602/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118880568 CMS
Otsuka America Pharmaceutical, Inc. $3.6002/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118880570 CMS
Otsuka America Pharmaceutical, Inc. $24.5002/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118880566 CMS
Teva Pharmaceuticals USA, Inc. $16.6701/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151720542 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $24.3001/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143211900 CMS
Otsuka America Pharmaceutical, Inc. $18.2601/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118880564 CMS
ABBVIE INC. $13.3501/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103520492 CMS
Teva Pharmaceuticals USA, Inc. $18.3401/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151720528 CMS
Otsuka America Pharmaceutical, Inc. $22.7301/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118880562 CMS
Noven Therapeutics, LLC $23.7401/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1084823251 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2022 $1,473.58 72
PY2023 $2,648.57 61
PY2024 $1,601.86 76
PY2025 $1,238.22 54

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,146,029.58 63
PY2024 Principal investigator $3,410,469.65 103
PY2023 Principal investigator $1,332,294.07 35
PY2022 Principal investigator $463,942.74 71
PY2021 Principal investigator $219,456.40 23
PY2020 Principal investigator $46,909.92 5
PY2019 Principal investigator $97,939.89 34

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

63 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,900.00 12/19/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049361
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $600.00 12/19/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049363
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,000.00 12/19/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049365
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,025.00 12/19/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049367
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,400.00 12/19/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049369
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,700.00 12/19/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049371
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $600.00 12/19/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049383
Principal investigator 1 Axsome Therapeutics, Inc. $5,572.97 12/11/2025 Non-covered Recipient Entity
Premier Clinical Research Institute
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199915700
Principal investigator 1 BioXcel Therapeutics, Inc. $8,200.00 12/01/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
BXCL501401 No dispute reported 06/30/2026 1228698332
Principal investigator 1 Axsome Therapeutics, Inc. $10,770.66 11/14/2025 Non-covered Recipient Entity
Premier Clinical Research Institute
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199915698
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $18,000.00 11/10/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment No dispute reported 06/30/2026 1242365937
Principal investigator 1 Axsome Therapeutics, Inc. $9,529.18 10/17/2025 Non-covered Recipient Entity
Premier Clinical Research Institute
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199915696
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,505.00 10/16/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049351
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $860.00 10/16/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049353
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $300.00 10/16/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049355
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $790.00 10/16/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049357
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,500.00 10/16/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049359
Principal investigator 1 Axsome Therapeutics, Inc. $13,063.00 09/15/2025 Non-covered Recipient Entity
Premier Clinical Research Institute
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199915694
Principal investigator 1 BioXcel Therapeutics, Inc. $9,733.82 09/15/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
BXCL501401 No dispute reported 06/30/2026 1228698230
Principal investigator 1 BioXcel Therapeutics, Inc. $2,927.95 09/15/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
BXCL501401 No dispute reported 06/30/2026 1228698232
Principal investigator 1 Axsome Therapeutics, Inc. $21,592.70 08/13/2025 Non-covered Recipient Entity
Premier Clinical Research Institute
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199915692
Principal investigator 1 BioXcel Therapeutics, Inc. $54,738.23 08/11/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
BXCL501401 No dispute reported 06/30/2026 1228698202
Principal investigator 1 Axsome Therapeutics, Inc. $14,430.76 07/23/2025 Non-covered Recipient Entity
Premier Clinical Research Institute
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199915690
Principal investigator 1 BioXcel Therapeutics, Inc. $37,262.35 07/08/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
BXCL501401 No dispute reported 06/30/2026 1228698178
Principal investigator 1 BioXcel Therapeutics, Inc. $65.63 07/08/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
BXCL501401 No dispute reported 06/30/2026 1228698180
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,815.00 07/04/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049335
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,935.00 07/04/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049337
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $16,280.00 07/04/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049339
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,250.00 07/04/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049341
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,700.00 07/04/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049343
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,025.00 07/04/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049345
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,500.00 07/04/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049347
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,500.00 07/04/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049349
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $84,303.48 07/02/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049333
Principal investigator 1 BioXcel Therapeutics, Inc. $86,839.56 06/19/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
BXCL501401 No dispute reported 06/30/2026 1228698076
Principal investigator 1 BioXcel Therapeutics, Inc. $31,500.00 06/19/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
BXCL501401 No dispute reported 06/30/2026 1228698086
Principal investigator 1 Axsome Therapeutics, Inc. $10,721.58 06/13/2025 Non-covered Recipient Entity
Premier Clinical Research Institute
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199915688
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $12,850.00 06/05/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049325
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $22,122.00 06/05/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049327
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,300.00 06/05/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049329
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $132,000.00 06/05/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049331
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,267.25 06/05/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049505
Principal investigator 1 BioXcel Therapeutics, Inc. $106,254.82 05/20/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
BXCL501401 No dispute reported 06/30/2026 1228698068
Principal investigator 1 Axsome Therapeutics, Inc. $6,255.45 05/16/2025 Non-covered Recipient Entity
Premier Clinical Research Institute
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199915686
Principal investigator 1 Axsome Therapeutics, Inc. $16,434.03 04/16/2025 Non-covered Recipient Entity
Premier Clinical Research Institute
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199915684
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $300.00 04/15/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049499
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,200.00 04/15/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049501
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $17,760.00 04/15/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049503
Principal investigator 1 BioXcel Therapeutics, Inc. $91,964.63 04/10/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
BXCL501401 No dispute reported 06/30/2026 1228697999
Principal investigator 1 BioXcel Therapeutics, Inc. $10,700.00 04/10/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
BXCL501401 No dispute reported 06/30/2026 1228698008
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $60,615.00 04/01/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049491
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $16,857.85 04/01/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049493
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $48,400.00 04/01/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049495
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $10,200.00 04/01/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049497
Principal investigator 1 Axsome Therapeutics, Inc. $14,455.92 03/24/2025 Non-covered Recipient Entity
Premier Clinical Research Institute
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199915682
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $16,975.71 03/18/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AVP-786 (DEUDEXTROMETHORPHAN HYDROBROMIDE [D6-DM]/QUINIDINE SULFATE [Q]) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMERS TYPE No dispute reported 06/30/2026 1225335701
Principal investigator 1 Axsome Therapeutics, Inc. $15,583.58 02/18/2025 Non-covered Recipient Entity
Premier Clinical Research Institute
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199915680
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,976.53 02/05/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049489
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,976.53 01/29/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049487
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,953.06 01/21/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049485
Principal investigator 1 Axsome Therapeutics, Inc. $22,479.29 01/14/2025 Non-covered Recipient Entity
Premier Clinical Research Institute
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199915678
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,976.53 01/07/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049481
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $28,734.53 01/07/2025 Non-covered Recipient Entity
PREMIER CLINICAL RESEARCH INSTITUTE INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049483